This Latin America Pharma Stock Rises 12% in 1 Year: What the Headline Hides
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Caplin Point: CMP Rs 2,600 (17 Sep 2026). Verified 1Y return 11.58%. 52W range Rs 1,500.30 to Rs 2,877.30. Market cap Rs 19,639 Cr. Q1 FY27 PAT Rs 179.09 Cr.
Quick Answer
Caplin Point Laboratories is the Latin America pharma stock that returned 11.58% in the year to 17 September 2026, rising from Rs 2,330.10 to Rs 2,600. The flat headline masks a fall to Rs 1,500.30 in March 2026 and a 73% rebound to a record Rs 2,877.30. Drivers were a ten-ANDA purchase, a Foscarnet Sodium approval and Q1 FY27 EBITDA growth of 23%, while a 194-day cash conversion cycle remains the drag.
This Latin America pharma stock rose approximately 12% in one year, a quiet headline hiding a violent round trip. The share closed at Rs 2,330.10 on 17 September 2025 and Rs 2,600 on 17 September 2026, a verified gain of 11.58%. It fell to Rs 1,500.30 in between, then hit a record Rs 2,877.30.
The company is Caplin Point Laboratories Ltd (NSE: CAPLIPOINT), a Chennai drugmaker selling branded generics and injectables across Central and South America, Africa and the US. Latin America gave 76% of FY26 operating revenue, the US 18% and Africa 6%, so the Caplin Point share price tracks an emerging-market distributor with a US option.
Click Here – Get Free Investment Predictions
How Has This Latin America Pharma Stock Performed Across Time Frames?
Over one year the Latin America pharma stock returned 11.58%, over six months around 59% and over five years close to 199%. These are close-to-close price returns to 17 September 2026, excluding dividends. No bonus issue or stock split fell in any window.
| Period | Starting Close | Close on 17 Sep 2026 | Price Return |
|---|---|---|---|
| 1 Month (17 Aug 2026) | Rs 2,522.00 | Rs 2,600.00 | 3.09% |
| 6 Months (17 Mar 2026) | Rs 1,635.10 | Rs 2,600.00 | 59.01% |
| 1 Year (17 Sep 2025) | Rs 2,330.10 | Rs 2,600.00 | 11.58% |
| 3 Years (15 Sep 2023) | Rs 1,044.80 | Rs 2,600.00 | 148.85% |
| 5 Years (17 Sep 2021) | Rs 870.95 | Rs 2,600.00 | 198.53% |
The three-year start is 15 September 2023 because 17 September 2023 was not a trading day. A Latin America pharma stock up 149% in three years but 12% in one has spent twelve months surrendering gains and rebuilding them. This one peaked near Rs 2,395 in September 2025, bottomed at Rs 1,500.30 on 30 March 2026, then rallied roughly 73%.
The Latin America pharma stock was among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026.
Why Did This Latin America Pharma Stock Rise Over the Past Year?
Four dated events between January and September 2026 lifted this Latin America pharma stock: an ANDA portfolio purchase, a high-value US injectable approval, a Q1 FY27 print with wider margins, and a Colombian clearance for the new oncology plant.
1. Ten Approved ANDAs Bought on 1 January 2026
On 1 January 2026 subsidiaries Caplin Steriles Ltd and Caplin One Labs Ltd acquired ten approved ANDAs from a multinational generic maker, covering injectable and ophthalmic products addressing a US market of USD 473.2 million in the twelve months to August 2025. Select oncology injectables move to the new Kakkalur site. The Latin America pharma stock closed 0.6% lower at Rs 1,827.10 that day.
2. Foscarnet Sodium Approval and a 20% Run to 10 June 2026
Caplin Steriles won final USFDA approval in May 2026 for Foscarnet Sodium Injection 6000 mg per 250 mL, a product with US sales of around USD 15 million in the twelve months to March 2026. The Caplin Point share price then gained 20.25% over five sessions ending 10 June 2026, including 5.18% on 10 June to Rs 2,374.45. One approval moved this Latin America pharma stock more than any regional tender that quarter.
3. Q1 FY27 Results on 12 August 2026
June-quarter revenue was Rs 610.36 crore, up 19.6%, EBITDA up 23% to Rs 247.03 crore and net profit up 18.8% to Rs 179.09 crore. The EBITDA margin widened to 38.4% from 37.1%, US subsidiary revenue tripled to Rs 43.1 crore and net worth rose 25% to Rs 3,776 crore.
The share fell 6.3% to about Rs 2,464 that day, on capacity rather than demand. Management said plants are booked out until February 2027 and called the shortage of lines the near-term bottleneck for this Latin America pharma stock.
4. Colombia’s INVIMA Clears the Oncology Plant on 5 September 2026
On 5 September 2026 Caplin One Labs received GMP compliance confirmation from Colombia’s regulator INVIMA for its Kakkalur facility in Tiruvallur district, covering sterile oncology injections plus oncology tablets and capsules. Oncology carries higher realisations than the legacy portfolio, and the Latin America pharma stock touched its record Rs 2,877.30 the same week.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Latin America and Africa: The Base Under This Latin America Pharma Stock
The regional mix sets both the margin and the working capital of this Latin America pharma stock. It owns front-end distribution in several Central American markets, holds over 4,000 registered licences and sells roughly 650 formulations across 36 therapeutic areas, which is why operating margins run near 35% to 40%.
Africa is only 6% of revenue and is where the spending is going: rest-of-world profitability fell to about 33% from 37.5% in Q1 FY27 on higher marketing costs. Management is evaluating buying a distributor in Mexico and has discussed manufacturing inside the region, and a large El Salvador tender supported the June quarter for this Latin America pharma stock.
Caplin Steriles and the US ANDA Push
Caplin Steriles is the sterile injectables arm and the reason this Latin America pharma stock is treated as more than a regional play. The group has 60 approved ANDAs with five under review, has launched 38 products and plans 12 more launches in FY27.
Manufacturing is the counterweight. Seven sterile injectable lines run today against a target of 17, with line seven starting in six to seven months and thirteen including oncology targeted by next year. Approvals are arriving faster than this Latin America pharma stock can make product.
Financials Behind This Latin America Pharma Stock
FY26 revenue was approximately Rs 2,187 crore, up around 15%, with net profit of Rs 649.73 crore after Rs 541.09 crore in FY25 and Rs 461.42 crore in FY24. Net profit margin has climbed from 24.3% in FY22 to 29.71%, book value is about Rs 443 and debt to equity is zero.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | Change |
|---|---|---|---|
| Revenue | Rs 610.36 Cr | Approximately Rs 510 Cr | Up 19.6% |
| EBITDA | Rs 247.03 Cr | Rs 200.90 Cr | Up 23.0% |
| EBITDA Margin | 38.4% | 37.1% | Up 130 bps |
| Net Profit | Rs 179.09 Cr | Rs 150.76 Cr | Up 18.8% |
| EPS (Diluted) | Rs 23.21 | Rs 20.03 | Up 15.9% |
| US Subsidiary Revenue | Rs 43.1 Cr | Rs 14.4 Cr | Up approximately 3x |
The Latin America pharma stock trades at a PE near 28.97 against an industry PE of about 37.40, with a price to book of 5.83 and a market capitalisation around Rs 19,639 crore. The FY26 dividend of Rs 8 per share goes to the annual general meeting called for 25 September 2026.
Receivables in Emerging Markets: The Weak Spot in This Latin America Pharma Stock
Working capital is why this Latin America pharma stock trades below its sector PE despite better margins. FY26 debtor days ran at approximately 138, inventory days at approximately 181 and the cash conversion cycle at about 194 days, so reported profit takes roughly six months to become cash.
Receivables rose again in the June 2026 quarter on government supplies, and inventory was lifted deliberately from Rs 429 crore to Rs 505 crore. Quarterly operating cash flow was Rs 98 crore, against Rs 523 crore for FY26.
Solvency is not the issue. The issue is that selling to public health systems means the buyer sets credit terms, and a Latin America pharma stock that funds its customers is one currency shock from a heavy provisioning quarter.
Shareholding Trend for This Latin America Pharma Stock
Promoter holding in this Latin America pharma stock has been flat at 70.57% for four quarters, leaving a free float under 30%. Foreign institutions trimmed from 6.17% in June 2025 to 5.75% in June 2026, while domestic institutions edged up to 2.49%.
| Shareholder | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 70.56% | 70.57% | 70.57% | 70.57% | 70.57% |
| FIIs | 6.17% | 6.51% | 6.59% | 6.15% | 5.75% |
| DIIs | 2.22% | 2.10% | 2.05% | 2.14% | 2.49% |
| Public | 21.05% | 20.82% | 20.79% | 21.14% | 21.18% |
That FII trim overlaps with the lows, so foreign selling was part of the drawdown in this Latin America pharma stock rather than a response to it. Domestic mutual funds, including a healthcare scheme, remain on the register.
Key Risks in This Latin America Pharma Stock
Regulatory risk: the USFDA inspected the Caplin Steriles plant at Gummidipoondi between 13 and 21 August 2026 and issued a Form 483 with ten observations. The company says none concern data integrity and none are repeat findings. A warning letter would stall the US pipeline this Latin America pharma stock is valued on.
Capacity caps growth: plants are booked to February 2027 and the move from seven to seventeen lines runs to 2029, so any delay pushes out revenue already priced in.
Country concentration: 76% of revenue sits in Latin America, so devaluation, import curbs, tender repricing or a fiscal squeeze in one or two countries would hit a large slice of group profit at once.
Liquidity and volatility: free float is below 30% with no derivatives segment, so exits move the price. This Latin America pharma stock fell from Rs 2,877.30 to Rs 2,490.50 inside two weeks in September 2026, and its 52-week range spans more than 90%.
Promoter and margin concerns: four individual promoters own more than 67% between them, so key-person dependence is real, and gross margin slipped to 59.8% from 61.7% in Q1 FY27.
Download the Univest iOS App or Univest Android App to track the Caplin Point share price live
Caplin Point Share: Analyst View
No verified current brokerage target could be confirmed for this Latin America pharma stock, so none is quoted here. At Rs 2,600 the Caplin Point share price values trailing earnings of Rs 89.20 per share at about 29 times, below the roughly 37 times the wider pharmaceutical set commands.
Three things decide the next move in this Latin America pharma stock: whether the Form 483 response closes cleanly, how fast injectable lines eight to thirteen start, and whether debtor days fall from 138.
Caplin Point Share Price Target
With no verified Caplin Point share price target available, traded levels are the honest reference for this Latin America pharma stock. The record Rs 2,877.30 sits about 11% above the current price and the 52-week low of Rs 1,500.30 about 42% below.
Any Caplin Point share price target published from here rests on assumptions about line commissioning and collection cycles. Check the date it carries, and whether it predates the August 2026 Form 483.
Other Stocks to Track From the Same Return Screen
Beyond this Latin America pharma stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Timex Group with a 1-year return of 80.30%, Cyient DLM at 80.04% and Karnataka Bank at 78.44%.
Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this Latin America pharma stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.
Conclusion
This Latin America pharma stock delivered 11.58% over the year, flattering neither the March 2026 collapse nor the 73% rebound that followed. The business compounded through both, with five straight years of profit growth, FY26 net profit of Rs 649.73 crore, zero debt and around Rs 1,500 crore of cash.
The bull case for the Latin America pharma stock is injectable capacity arriving on time and the US ANDA shelf converting into sales. The bear case is a 194-day cash cycle, an open Form 483 and 76% of revenue in countries whose health budgets set payment terms.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which Latin America pharma stock rose 12% in one year?
Ans. Caplin Point Laboratories (NSE: CAPLIPOINT) is the Latin America pharma stock that gained 11.58% between 17 September 2025 and 17 September 2026, from Rs 2,330.10 to Rs 2,600. It was among the stronger performers on a screen of NSE small-cap stocks ranked by 1-year return.
Why did the Caplin Point share price fall after Q1 FY27 results?
Ans. The Caplin Point share price fell 6.3% to about Rs 2,464 on 12 August 2026 because management flagged capacity as the main growth constraint. Revenue rose 19.6% and net profit 18.8%, but plants are booked out until February 2027.
How much of Caplin Point revenue comes from Latin America?
Ans. Latin America contributed 76% of FY26 operating revenue for this Latin America pharma stock, the United States 18% and Africa 6%. It owns front-end distribution in several Central American markets.
What is the 52-week high and low of the Caplin Point share price?
Ans. The 52-week high is Rs 2,877.30, made in the first week of September 2026, and the 52-week low is Rs 1,500.30, made on 30 March 2026. That range of more than 90% shows how volatile this Latin America pharma stock has been.
Is there a verified brokerage target for Caplin Point?
Ans. No verified current Caplin Point share price target could be confirmed, so none is quoted. Useful reference levels for this Latin America pharma stock are the record high of Rs 2,877.30 and the 52-week low of Rs 1,500.30.
What did the USFDA Form 483 at Caplin Steriles say?
Ans. The USFDA inspected the Caplin Steriles injectable and ophthalmic plant at Gummidipoondi between 13 and 21 August 2026 and issued a Form 483 with ten observations. The company stated that none relate to data integrity and none are repeat findings.
Why are receivables a concern for this Latin America pharma stock?
Ans. Debtor days ran at approximately 138 in FY26 with a cash conversion cycle near 194 days, because much of the business is sold to public health systems that set payment terms. Operating cash flow of Rs 523 crore and a Rs 1,500 crore cash balance cushion the strain.
Has Caplin Point announced any bonus issue or stock split recently?
Ans. No bonus issue or stock split took place in the one-year, three-year or five-year windows used here, so the returns shown for this Latin America pharma stock are pure price appreciation. Face value remains Rs 2 per share.
